TY - JOUR AU - Jarajreh, Dua’a AU - Aqel, Amin AU - Alzoubi, Hamed AU - Al-Zereini, Wael PY - 2017/04/30 Y2 - 2024/03/29 TI - Prevalence of inducible clindamycin resistance in methicillin-resistant Staphylococcus aureus: the first study in Jordan JF - The Journal of Infection in Developing Countries JA - J Infect Dev Ctries VL - 11 IS - 04 SE - Brief Original Articles DO - 10.3855/jidc.8316 UR - https://jidc.org/index.php/journal/article/view/28459227 SP - 350-354 AB - <p class="SmallText">Introduction: A high rate of infections with methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) has been documented, in both hospital- (HA-MRSA) and community-acquired (CA-MRSA) diseases in Jordan. Erythromycin and clindamycin are considered treatments of choice. However, resistance to erythromycin with false susceptibility to clindamycin <em>in vitro </em>may lead to therapeutic failure. Hence, it is mandatory to study the prevalence of inducible resistance to macrolide-lincosamide-streptogramin B (iMLS<sub>B</sub>) antibiotics conferred by <em>erm </em>genes in those bacteria.</p> <p class="SmallText">Methodology: <em>S. aureus </em>isolates were identified morphologically and biochemically, and MRSA were appraised using standard procedures. Induction in resistance to MLS<sub>B </sub>antibiotics among MRSA isolates was detected phenotypically using the D-test, and the presence of <em>erm </em>genes was revealed by polymerase chain reaction (PCR).</p> <p class="SmallText">Results: Of 126 collected<em> Staphylococcus </em>isolates, 71 (56.3%) isolates were <em>S. aureus</em>, of which 55 (77.5%) were MRSA. A total of 43 (78.2%) MRSA-discordant isolates were resistant to erythromycin, of which 33 (76.7%) exhibited the iMLS<sub>B</sub> (D-test positive), 2 (4.7%) the MS<sub>B</sub> (D-test negative), and 8 (18.6%) the constitutive resistant (cMLS<sub>B</sub>) phenotypes. Induction of clindamycin resistance was 1.6 times greater in CA-MRSA than in HA-MRSA. Furthermore, <em>ermA</em> and <em>ermC</em> were significantly prevalent in HA-MRSA and CA-MRSA, respectively.</p> <p class="SmallText">Conclusions: Continuous surveillance of the MLS<sub>B</sub> resistance is important and required before the prescription of clindamycin to treat MRSA infections.</p> ER -